Healthcare entity

BPC-157

Product

regulation is the sole category represented across all 4 tracked stories. Of the tracked stories, 4 of 4 also mention TB-500, the most common co-covered peer. That works out to roughly 2.8 stories per week across a 10-day span. The busiest single day carried 2.

Last mentioned: Aug 3, 2026

RSS updates
Share

Entity pulse

Recent coverage · BPC-157

↑
4 stories
5.8 avg impact
75% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 75 percentage points.

  • 75% positive
  • 25% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about BPC-157

regulation is the sole category represented across all 4 tracked stories. Of the tracked stories, 4 of 4 also mention TB-500, the most common co-covered peer. That works out to roughly 2.8 stories per week across a 10-day span. The busiest single day carried 2. Each story carries 2.5 original sources on average, compared with 2.3 for the broader beat in this window. At 5.8, the average consequence score sits above the same-window beat average of 5.7. This profile follows 4 Healthcare stories mentioning BPC-157 across the period from July 27, 2026 to August 5, 2026.

Stories tracked
4
Per week
2.8
Sources per story
2.5

Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 108 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering BPC-157. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. PCAC Votes to Recommend Six Peptides

    The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.

  2. Advisory meeting concludes

    The committee is expected to wrap up its evaluation and make recommendations that will guide the FDA's future compounding policy for peptides.

  3. FDA PCAC Public Meeting Begins

    The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.

Stories mentioning BPC-157 4

Health Policy Neutral

FDA Panel Reviews 7 Injectable Peptides Poised to Disrupt Telehealth and Longevity Care

The FDA’s advisory committee meeting on seven unapproved injectable peptides could reshape the rapidly growing telehealth and wellness industry. A decision to allow compounding would legitimize a key offering for direct-to-consumer platforms, while a restrictive stance may intensify safety risks from the gray market. Healthcare providers and digital health innovators are watching closely.

3 sources

Source: kpbs.org · wkyufm.org

Health Policy Positive

FDA Panel's 8-6 Vote Opens Door for Peptide-Fueled Telehealth Boom

A narrow FDA advisory panel vote to ease peptide compounding restrictions could trigger a rapid expansion of telehealth-delivered wellness treatments, despite a stark lack of safety data. With HHS Secretary RFK Jr. supporting access, healthcare providers must prepare for a new era of direct-to-consumer peptide therapies.

2 sources

BPC-157 is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.